Humacyte, Inc. (HUMA) closed the most recent trading day at $0.78, moving -2.32% from the previous trading session. This change lagged the S&P 500's 0.79% gain on the day. Meanwhile, the Dow ...

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 17, 2025 deadline to participate as a lead plaintiff in the securities fraud class action ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Humacyte, Inc. (HUMA) been one of those stocks this year? By ...

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results ...

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...